Ezad Saad M, Ryan Matthew, Perera Divaka
British Heart Foundation Centre of Research Excellence and NIHR Biomedical Research Centre at the School of Cardiovascular Medicine and Sciences, King's College London, London, UK.
Heart Int. 2022 Dec 21;16(2):72-74. doi: 10.17925/HI.2022.16.2.72. eCollection 2022.
Coronary artery disease (CAD) remains the most common cause of heart failure with reduced ejection fraction; despite its prevalence, there is limited evidence to guide physicians in managing patients with CAD with percutaneous revascularization. The REVIVED-BCIS2 trial (ClinicalTrials.gov identifier: NCT01920048) represents the first randomized trial to assess the value of percutaneous coronary intervention in addition to optimal medical therapy in patients with ischaemic left ventricular systolic dysfunction and stable CAD. In this article, we review the results of the REVIVED-BCIS2 trial and compare them to the ClinicalTrials.gov Identifier: NCT00023595 trial (ClinicalTrials.gov Identifier: NCT00023595), which investigated the benefit of surgical revascularization on such patients. Finally, we suggest a pathway for physicians managing patients with ischaemic left ventricular systolic dysfunction based on the current evidence and highlight potential avenues for future research.
冠状动脉疾病（CAD）仍然是射血分数降低的心力衰竭的最常见原因；尽管其患病率很高，但指导医生对CAD患者进行经皮血运重建治疗的证据有限。REVIVED-BCIS2试验（ClinicalTrials.gov标识符：NCT01920048）是第一项评估在缺血性左心室收缩功能障碍和稳定CAD患者中，除最佳药物治疗外，经皮冠状动脉介入治疗价值的随机试验。在本文中，我们回顾了REVIVED-BCIS2试验的结果，并将其与ClinicalTrials.gov标识符：NCT00023595试验（ClinicalTrials.gov标识符：NCT00023595）进行比较，该试验研究了此类患者手术血运重建的益处。最后，我们根据当前证据为管理缺血性左心室收缩功能障碍患者的医生提出了一条途径，并强调了未来研究的潜在方向。
